Diphtheria tetanus acellular pertusis inactivated poliovirus haemophilus influenza type B-hepatitis B combined hexavalent vaccine - BioNet Asia/Pharmaniaga
Alternative Names: Diphtheria, tetanus, acellular pertusis, inactivated poliovirus, haemophilus influenza type B, hepatitis B vaccine - BioNet Asia/Pharmaniaga; DTaP-IPV-Hib-HB combination vaccine - BioNet Asia/Pharmaniaga; DTaP-poliovirus-Hib-HB combination vaccine - BioNet Asia/Pharmaniaga; Hexavalent Vaccine - BioNet Asia/PharmaniagaLatest Information Update: 10 Mar 2023
At a glance
- Originator BioNet-Asia; Pharmaniaga
- Class Bacterial vaccines; Haemophilus vaccines; Hepatitis B vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 13 Dec 2022 Pharmaniaga and BioNet entered into research agreement for development of Diphtheria tetanus acellular pertusis inactivated poliovirus haemophilus influenza type B-hepatitis B combined hexavalent vaccine for Diphtheria, Tetanus, Pertussis, Poliomyelitis, Haemophilus, and Hepatitis B
- 13 Dec 2022 Early research in Diphtheria (Prevention) in Malaysia (Parenteral)
- 13 Dec 2022 Early research in Haemophilus infections (Prevention) in Malaysia (Parenteral)